Researchers developed a bsAb targeting B7-H3 and 4-1BB, which enhanced the proliferation and cytokine production of terminally differentiated CD8+ tumor-infiltrating lymphocytes, thereby enhancing antitumor immunity (121). This evidence concerns the gene CD8A and neoplasm.